CJC-1295 No DAC: 200mcg PM, 5-On/2-Off

CJC-1295 no DAC (also known as modified GRF 1-29) is a synthetic GHRH analog with four amino acid substitutions for improved stability and a short-acting ~30-minute half-life that produces pulsatile GH release mimicking the body's natural secretion pattern. No human clinical trials exist for the no-DAC form. Community protocols are based on GHRH pharmacology and the DAC version's clinical data. This is not medical advice.

Research-context information only. CJC-1295 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Standard Protocol

The standard protocol is 200 mcg before bed, 5 days on / 2 days off, for 8 weeks. CJC-1295 no DAC is almost always paired with a GHRP (ipamorelin, GHRP-2, or GHRP-6) for synergistic GH release. Community sources consistently describe standalone results as modest compared to GHRP-stacked protocols.

Cycling: 8 Weeks On, 8 Weeks Off

Run 200 mcg before bed, 5 days on / 2 days off, for 8 weeks. Then take 8 weeks off — community sources generally frame the break around cost and letting IGF-1 normalize between blocks. No long-term trials have evaluated continuous CJC-1295 use, so the on/off pattern community sources describe is a convention rather than a desensitization-validated requirement. No loading phase needed. IGF-1 blood work before, during, and after cycles helps gauge response. For background, see Do GH Peptides Desensitize the Pituitary?.

Flushing and head rush are common in the first 1-2 weeks and typically resolve.

PM timing is critical: The pre-bed injection amplifies the natural nocturnal GH surge -- the largest GH pulse of the day. Community protocols describe injecting on an empty stomach. Carbohydrates and fats suppress GH release via insulin and somatostatin.

Routes of Administration

Subcutaneous injection (standard): Abdomen, love handles, or thighs. Very small injection volume (typically 0.05-0.06 mL). 29-31 gauge insulin syringe. Trial protocols describe rotating injection sites to minimize lipodystrophy risk.

Reconstitution Quick Reference

Math: 10,000 mcg / 3 mL = 3,333 mcg/mL. For 200 mcg: 200 / 3,333 = 0.06 mL = 6 units. One vial lasts 50 doses.

Community protocols describe gentle swirling — not shaking — to avoid degradation, with storage at 2–8°C and use within 28 days. For step-by-step instructions, see the CJC-1295 Reconstitution Guide.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

CJC-1295 clinical research primarily used the DAC version, but the pharmacology informs no-DAC protocols.

Pivotal human study: Teichman et al. examined CJC-1295 (with DAC) in 36 healthy adults (21-61 years). Single doses of 30-120 mcg/kg produced dose-dependent GH and IGF-1 increases, with IGF-1 elevated 1.5-3 fold for 6-14 days (Teichman et al., 2006).

Preserved pulsatility: A follow-up confirmed that despite continuous GHRH stimulation, pulsatile GH secretion was maintained -- GH pulse frequency preserved with 2-fold increases in mean GH and pulse mass (Ionescu & Bhatt, 2006).

Animal studies: CJC-1295 normalized growth in GHRH knockout mice with once-daily dosing (Alba et al., 2006).

Why no-DAC is preferred by many: Short half-life produces pulsatile rather than sustained GH elevation, more closely mimicking natural GHRH/GH secretion. Lower baseline GH between pulses. Controllable timing windows. Optimal synergy with timed GHRP co-injection.

Stacking Protocols

Stacking tips: Community protocols describe injecting GHRH + GHRP simultaneously for synergistic effect. Community sources describe drawing both into one insulin syringe. Community protocols describe the fasted state as critical for GH response. Community sources consistently describe the pre-bed injection as the highest-priority timing window.

For the detailed blend protocol, see our CJC-1295 + Ipamorelin Dosing Guide.

Side Effects & Safety

• Flushing/warmth -- very common in first 1-2 weeks, transient (15-30 min post-injection)
• Head rush/dizziness -- brief, typically resolves quickly
• Injection site reactions -- mild redness, occasional irritation
• Water retention -- mild, GH-mediated sodium retention
• Tingling/numbness -- occasional, related to GH effects
• Vivid dreams -- frequently reported, likely from enhanced deep sleep
• Insulin resistance -- chronic GH elevation can impair glucose tolerance (monitor fasting glucose)
• Contraindications -- active malignancy, diabetic retinopathy, pregnancy

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once CJC-1295 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 5 mL BAC water (2 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.